great resource, page-5

as we know - only one therapuetic to go commercial is all that's required. we'd then be sorted without needing the patents.

what is important, is the patent position is not important as a blunt means to a revenue stream, but rather strategic positioning of the company in the right programmes with the right terms.

blt have the upper hand, the high ground, the twin turbo V8, enabling it to manouvre into a poll position for probably more than one blockbuster before the overarching patents expire.

If it's of concern to the market, then on the upside risk they'd do well to factor in a strong case for CSIRO to extend the US '099 patent another 4 years to 2022, because of the patent examiner's not understanding some very fundamental points and thus delaying the patent re-award. The BPAI Judges at the USPTO have already provided the material for this case in their unconditional dismissal of all the examiner's arguments.

But Benitec via CSIRO aren't playing this card yet, and maybe do not need to ever at all, because they have plenty of programmes going on, and patents specific to target diseases that go well past 2020.